|
Feb 14
|
TC BioPharm completes dosing in Cohort A of Phase IIb trial for AML
|
|
Feb 13
|
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
|
|
Feb 10
|
TC BioPharm Completes Initial Group B Dosing in Trial of TCB008 to Treat Acute Myeloid Leukemia
|
|
Feb 10
|
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
|
|
Dec 31
|
Sector Update: Health Care Stocks Mixed Late Afternoon
|
|
Dec 31
|
TCBP Provides Update on Acquisition Strategy and Current Targets
|
|
Dec 30
|
TCBP Issues 25% Stock Dividend
|
|
Oct 3
|
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
|
|
Sep 12
|
TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
|
|
Sep 9
|
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
|
|
Aug 29
|
TC BioPharm secures European patent for cancer treatment
|
|
Aug 28
|
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering
|
|
Aug 28
|
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
|
|
Jul 31
|
TCBP Announces Plan to Implement ADS Ratio Change
|
|
Jul 22
|
TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia
|
|
Feb 15
|
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe
|
|
Feb 14
|
TCBP Provides Shareholder Update and Highlights Upcoming Milestones
|
|
Dec 22
|
TC BioPharm Announces Closing of $3.5 Million Public Offering
|
|
Dec 19
|
TC BioPharm Announces Pricing of $3.5 Million Public Offering
|
|
Dec 18
|
TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D
|